Legacy Capital Wealth Partners LLC Invests $228,000 in Enovis Co. (NYSE:ENOV)

Legacy Capital Wealth Partners LLC bought a new position in Enovis Co. (NYSE:ENOV) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,192 shares of the company’s stock, valued at approximately $228,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ENOV. Raymond James & Associates increased its position in shares of Enovis by 1,076.7% in the 3rd quarter. Raymond James & Associates now owns 56,692 shares of the company’s stock worth $2,441,000 after purchasing an additional 51,874 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of Enovis by 9.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock valued at $667,000 after buying an additional 1,400 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Enovis during the 3rd quarter valued at about $55,000. State of Alaska Department of Revenue grew its position in shares of Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company’s stock valued at $279,000 after buying an additional 1,115 shares during the last quarter. Finally, Tributary Capital Management LLC grew its position in shares of Enovis by 3.3% during the 3rd quarter. Tributary Capital Management LLC now owns 422,831 shares of the company’s stock valued at $18,203,000 after buying an additional 13,641 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

NYSE ENOV opened at $43.89 on Tuesday. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -20.04 and a beta of 1.94. The company has a 50-day moving average price of $45.30 and a two-hundred day moving average price of $44.33.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $64.83.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.